Abstract
Resistance to CCR5 antagonists can be driven by mutations in gp120. Sequences from 323 anti-CCR5 naive patients were analyzed for the presence of previously described in-vivo or in-vitro resistance mutations to CCR5 antagonists located in the V3 loop of gp120. The V3 loop region was rather polymorphic, and 7.3% of patients showed viruses with combinations of mutations in V3 loop previously described to be involved in maraviroc resistance, a licensed CCR5 antagonist.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
CCR5 Receptor Antagonists*
-
Cyclohexanes / pharmacology
-
Drug Resistance, Viral / genetics*
-
Genotype
-
HIV Envelope Protein gp120 / genetics
-
HIV Fusion Inhibitors / pharmacology*
-
HIV-1 / drug effects*
-
HIV-1 / genetics
-
Humans
-
Maraviroc
-
Mutation
-
Triazoles / pharmacology
Substances
-
CCR5 Receptor Antagonists
-
Cyclohexanes
-
HIV Envelope Protein gp120
-
HIV Fusion Inhibitors
-
Triazoles
-
gp120 protein, Human immunodeficiency virus 1
-
Maraviroc